160 related articles for article (PubMed ID: 31017473)
1. Anti-miRNA21 and resveratrol-loaded polysaccharide-based mesoporous silica nanoparticle for synergistic activity in gastric carcinoma.
Hu Y; Wang Z; Qiu Y; Liu Y; Ding M; Zhang Y
J Drug Target; 2019 Dec; 27(10):1135-1143. PubMed ID: 31017473
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer.
Lin M; Yao W; Xiao Y; Dong Z; Huang W; Zhang F; Zhou X; Liang M
Bioengineered; 2021 Dec; 12(1):6343-6353. PubMed ID: 34506231
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
5. MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma.
Yang H; Liu Y; Qiu Y; Ding M; Zhang Y
Int J Pharm; 2019 Jul; 566():585-593. PubMed ID: 31181310
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronidase Enzyme-responsive Targeted Nanoparticles for Effective Delivery of 5-Fluorouracil in Colon Cancer.
Jiang H; Shi X; Yu X; He X; An Y; Lu H
Pharm Res; 2018 Feb; 35(4):73. PubMed ID: 29476264
[TBL] [Abstract][Full Text] [Related]
8. Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells.
Wang Z; Tian Y; Zhang H; Qin Y; Li D; Gan L; Wu F
Int J Nanomedicine; 2016; 11():6485-6497. PubMed ID: 27980406
[TBL] [Abstract][Full Text] [Related]
9. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
10. Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy.
Fang J; Zhang S; Xue X; Zhu X; Song S; Wang B; Jiang L; Qin M; Liang H; Gao L
Int J Nanomedicine; 2018; 13():5113-5126. PubMed ID: 30233175
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
12. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation.
Liu K; Wang ZQ; Wang SJ; Liu P; Qin YH; Ma Y; Li XC; Huo ZJ
Int J Nanomedicine; 2015; 10():6445-54. PubMed ID: 26491300
[TBL] [Abstract][Full Text] [Related]
15. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
[TBL] [Abstract][Full Text] [Related]
17. pH-responsive nanoreservoirs based on hyaluronic acid end-capped mesoporous silica nanoparticles for targeted drug delivery.
Chen C; Sun W; Wang X; Wang Y; Wang P
Int J Biol Macromol; 2018 May; 111():1106-1115. PubMed ID: 29357289
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Gao Z; Li Z; Yan J; Wang P
Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
Yu M; Jambhrunkar S; Thorn P; Chen J; Gu W; Yu C
Nanoscale; 2013 Jan; 5(1):178-83. PubMed ID: 23076766
[TBL] [Abstract][Full Text] [Related]
20. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
